Key points are not available for this paper at this time.
Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. (Funded by Cancer Research UK and others; ClinicalTrials.gov number, NCT01682772; Cancer Research UK number, CRUK/11/029.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Joaquı́n Mateo
Suzanne Carreira
Shahneen Sandhu
New England Journal of Medicine
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)
The Medicine Forum
University of Michigan
Cornell University
University College London
Building similarity graph...
Analyzing shared references across papers
Loading...
Mateo et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d978441ad561c67368453b — DOI: https://doi.org/10.1056/nejmoa1506859